Journal
CANCER CELL
Volume 37, Issue 4, Pages 471-484Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2020.03.007
Keywords
-
Categories
Funding
- National Cancer Institute [R35CA197623, R00CA201606]
- Susan G. Komen Breast Cancer Foundation [CCR17481976]
- Breast Cancer Research Foundation
Ask authors/readers for more resources
Advances in our understanding of molecular mechanisms of tumorigenesis have translated into knowledge-based therapies directed against specific oncogenic signaling targets. These therapies often induce dramatic responses in susceptible tumors. Unfortunately, most advanced cancers, including those with robust initial responses, eventually acquire resistance to targeted therapies and relapse. Even though immune-based therapies are more likely to achieve complete cures, acquired resistance remains an obstacle to their success as well. Acquired resistance is the direct consequence of pre-existing intratumor heterogeneity and ongoing diversification during therapy, which enables some tumor cells to survive treatment and facilitates the development of new therapy-resistant phenotypes. In this review, we discuss the sources of intratumor heterogeneity and approaches to capture and account for it during clinical decision making. Finally, we outline potential strategies to improve therapeutic outcomes by directly targeting intratumor heterogeneity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available